Compare Cigna Corp (CI) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.36. The key difference: Cigna Corp pays a 2.24% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Cigna Corp nearer its low. Which is the better fit depends on your goals.
| CI | QQQE | |
|---|---|---|
Market Cap | $73.56B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $311.00 | $122.72 |
52-Week Low | $244.41 | $96.06 |
Enterprise Value | $98.27B | — |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
QQQE trades at $121.96, up 1.61% with strong bullish technical signals from moving averages. The equal-weighted Nasdaq-100 ETF offers diversified exposure to large-cap growth stocks, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential Nasdaq-100 inclusion as a catalyst for equal-weighted strategies.
The ETF's equal-weight approach provides defensive positioning amid tech concentration concerns, with recent outperformance driven by mid-tier growth and biotech exposure. Key risks include market volatility and tech sector sensitivity, while institutional interest grows due to balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
